| CT1 study |  | CT2 study | ||||
---|---|---|---|---|---|---|---|
Total, N (%) | Crude prevalence, N (%) | Weighteda prevalence, % (95% CI) | Total, N (%) | Crude prevalence, N (%) | Weightedb prevalence, % (95% CI) | ||
Total | 770 | 11 (1.43) | 1.54 (0.78–3) | Total | 763 | 10 (1.31) | 1.76 (0.63–4) |
Gender | Gender | ||||||
Male | 348 (45%) | 5 (1.44) | 1.75 (0.62–4) | Male | 351 (46%) | 3 (0.86) | 2.25 (0.45–6) |
Female | 422 (55%) | 6 (1.42) | 1.32 (0.52–3) | Female | 412 (54%) | 7 (1.70) | 1.29 (0.39–3) |
Age groups total | Age groups total | ||||||
16–29 y/o | 181 (24%) | 3 (1.66) | 1.54 (0.38–4) | 18–29 y/o | 125 (16%) | 3 (2.40) | 3.54 (0.35–13) |
30–44 y/o | 279 (36%) | 5 (1.79) | 2.07 (0.69–5) | 30–44 y/o | 299 (39%) | 2 (0.67) | 1.04 (0.08–4) |
45–59 y/o | 310 (40%) | 3 (0.97) | 1.01 (0.24–3) | 45–59 y/o | 339 (44%) | 5 (1.47) | 1.56 (0.44–4) |
Age groups men | Age groups men | ||||||
16–29 y/o | 86 (25%) | 2 (2.33) | 2.15 (0.34–7) | 18–29 y/o | 59 (17%) | 1 (1.69) | 5.57 (0.30–23) |
30–44 y/o | 114 (33%) | 2 (1.75) | 2.40 (0.39–7) | 30–44 y/o | 130 (37%) | 1 (0.77) | 2.07 (0.11–9) |
45–59 y/o | 148 (43%) | 1 (0.68) | 0.81 (0.04–4) | 45–59 y/o | 162 (46%) | 1 (0.62) | 0.66 (0.04–3) |
Age groups women | Age groups women | ||||||
16–29 y/o | 95 (23%) | 1 (1.05) | 0.91 (0.05–4) | 18–29 y/o | 66 (16%) | 2 (3.03) | 1.12 (0.15–4) |
30–44 y/o | 165 (39%) | 3 (1.82) | 1.75 (0.43–5) | 30–44 y/o | 169 (41%) | 1 (0.59) | 0.16 (0.08–1) |
45–59 y/o | 162 (38%) | 2 (1.23) | 1.22 (0.2–4) | 45–59 y/o | 177 (43%) | 4 (2.26) | 2.40 (0.53–6) |